14 results about "Long acting" patented technology

Provided herein are variant α4β7 integrin antibodies and methods of use.

The invention discloses a long-acting pellet suitable for gastric absorption and a preparation method of the long-acting pellet. The long-acting pellet is prepared from the following components in parts by mass: 0.01-1 part of a medicine, 1-2.5 parts of a filler, 0.2-0.7 part of a modified pore-foaming agent mixture, 1-2.5 parts of an improved adhesive mixture and 0.1-0.7 part of an improved sonokinetic response agent. Wherein the modified pore-foaming agent mixture is prepared from a modified pore-foaming agent and glycosylated saponin, the modified pore-foaming agent is prepared by mixing a pore-foaming agent and seleno-amino acid according to a mass ratio of 4: 1, the improved adhesive is mixed with the adhesive through BHP-SH, and ionic crosslinking is performed by using CaCl2 to form a covalent ion dual network, so that the stomach adhesiveness is enhanced; the sonokinetic response agent is improved by the coated poria cocos extract, and the long-acting pellet is prepared by adopting a wet granulation method or a fluidized bed method, has the characteristics of slow release, long acting, targeted stomach absorption and responsive drug release, and is suitable for treating stomach diseases such as gastritis.

Provided herein are variant α4β7 integrin antibodies and methods of use.

The invention relates to a method for altering the release characteristics of a long acting drug delivery device containing at least two drugs in different segments, wherein the segments are arranged to a specific sequence.The invention furthermore relates to a drug delivery device with reduced initial burst containing two different drugs in different segments.The invention further relates to a delivery device manufactured according to the a.m. method and its use in contraception and gynecological therapies.

Disclosed herein are polymeric nanoparticles containing peptides, which provide low burst release and sustained, delivery of the peptides, and pharmaceutical compositions thereof. The polymeric nanoparticles contain a peptide encapsulated or dispersed therein. The nanoparticles can provide sustained release of the peptide, for example, less than 20% of the peptide is released initially (at time 0 hour) following placement into a phosphate buffered saline at pH 7.4 at 37° C. and room pressure. Methods for micronizing a peptide and for preparing polymeric nanoparticles containing solid, micronized peptides are also disclosed. The preparation methods use miscible solvent and non-solvent pairs in phase inversion nanoencapsulation processes. The Gibbs energy of mixing (ΔGMix) between the solvent and non-solvent can be tailored to achieve desired particle size, encapsulation efficiency, and release profile.

The present invention relates to long acting glucagon-like peptide-1 and human glucose-dependent insulinotropic polypeptide (GIP) dual agonist polypeptide which may be useful for treating type 2 diabetes mellitus (T2D), diabetes with obesity, obesity and hyperlipidemia.

Provided herein are anti-avb6 integrin engineered polypeptides, fusion proteins thereof with an Fc domain, and pharmaceutically acceptable compositions comprising the same. The anti-avb6 integrin engineered polypeptides of the present technology selectively bind the avb6 integrin with low-nanomolar or picomolar binding activity.

Methods of preventing the side effects of antibody drug conjugate therapies and other long acting emetogenic therapies such as nausea and vomiting, particularly in the long-delayed phase (i.e. > 120 hours).

The present application belongs to the technical field of cattle breeding, and provides a method for promoting the development of bovine follicles by injecting long-acting recombinant follicle-stimulating hormone into the urogenital mesoderm. The method comprises injecting an effective dose of long-acting recombinant follicle-stimulating hormone into the urogenital mesoderm of a cow. By injecting long-acting recombinant follicle-stimulating hormone (LArF) into the urogenital mesoderm, slow, continuous and direct action can be achieved, while off-target effects and pain are minimized. In addition, by using the minimum injection volume, the risk associated with the injection operation can be further reduced. In addition, the urogenital mesoderm injection scheme has the advantages of simpler operation, higher safety, less stress, more efficient process and lower cost under the premise of ensuring the follicle size and oocyte number required for oocyte collection.

The present disclosure provides a GLP1 analogue and a GLP1 / GIP receptor co-agonist analogue, a fusion protein comprising the GLP1 analogue or the GLP1 / GIP receptor co-agonist analogue, and methods of use thereof. In various embodiments, the fusion protein comprises the GLP1 analogue or the GLP1 / GIP receptor co-agonist analogue, which is fused to a protective antibody, or further fused to a stabilizing domain. In one embodiment, the fusion protein can be used to treat or ameliorate symptoms or indications of diseases such as obesity and diabetes.

Methods of preventing the side effects of antibody drug conjugate therapies and other long acting emetogenic therapies such as nausea and vomiting, particularly in the long-delayed phase (i.e. >120 hours).

The invention provides collagen as well as a preparation method and a preparation thereof. The method comprises the following steps: dissolving a collagen extract in acid, sequentially carrying out 450 kDa-550 kDa membrane ultrafiltration and two times of 250 kDa-350 kDa membrane concentration treatment, and further carrying out crosslinking and sterilization on the prepared collagen concentrated solution to prepare the collagen. According to the method, impurities and immune sources in the collagen extract are removed through ultrafiltration and two times of concentration treatment, purification of the collagen extract is achieved, the molecular weight and distribution of collagen are regulated and controlled, and therefore the crosslinking degree and crosslinking stability of the collagen are regulated and controlled. The collagen prepared by the invention has excellent stability and biodegradability resistance, can be widely applied to the fields of medical instruments, medical cosmetology and the like, and has the advantage of long acting time.

The invention provides a sustained-release microsphere patch containing growth factors and application of the sustained-release microsphere patch in repairing pressure sore wounds. The patch comprises a backing layer, a drug-loaded microsphere layer and a protective stripping liner, the drug-loaded microsphere layer is composed of sustained-release microspheres dispersed in a medical adhesion matrix, the sustained-release microspheres are formed by wrapping basic fibroblast growth factors and epidermal growth factors with carboxyl-terminated PLGA, the mass ratio of the basic fibroblast growth factors to the epidermal growth factors is 1: (2-3), the sustained-release microspheres with the high encapsulation efficiency are prepared through a W / O / W multiple emulsion method, and controllable release of the growth factors is achieved; and chitosan modified nano-silver is added to enhance the antibacterial property, so that the patch can remarkably promote granulation tissue growth and epithelium repair, is effectively used for II-IV stage pressure sore wound treatment, and has the advantages of slow release, long acting, infection reduction and convenience in use.

The present invention provides a method of treating patients with long acting injectable paliperidone palmitate formulations.